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Abstract
Objective
AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase critically involved
in the regulation of cellular energy homeostasis. It is a central regulator of both lipid and glu-
cose metabolism. Many studies have suggested that AMPK activation exert significant anti-
inflammatory and immunosuppressive effects. In this study, we assessed whether targeted
activation of AMPK inhibits inflammatory arthritis in vivo.
Methods
We tested the effect of A-769662, a specific AMPK agonist (60mg/kg/bid) in mouse models
of antigen-induced arthritis (AIA) and passive K/BxN serum-induced arthritis. The passive
K/BxN serum-induced arthritis model was also applied to AMPKα1-deficient mice. Joints
were harvested and subjected to histological analysis. IL-6 expression was measured in
both joint tissues and sera by ELISA. The effect of A-769662 on bone marrow derived mac-
rophage (BMDM) response to stimulation with TLR2 and TLR4 agonists was tested in vitro.
Results
AMPK activation by A-769662 reduced inflammatory infiltration and joint damage in both
mouse models. IL-6 expression in serum and arthritic joints was significantly decreased in
A-769662-treated mice. AMPKα1 deficient mice mildly elicited an increase of clinical arthri-
tis. IL-6 expression at both mRNA and protein levels, phosphorylation of p65 NF-κB and
MAPK phosphorylation were inhibited by A-769662 in BMDMs stimulated with either TLR2
or TLR4 agonists.
Conclusions
AMPK activation by specific AMPK agonist A-769662 suppressed inflammatory arthritis in
mice as well as IL-6 expression in serum and arthritic joints. These data suggest that
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targeted activation of AMPK has a potential to be an effective therapeutic strategy for IL-6
dependent inflammatory arthritis.
Introduction
AMPK is a crucial regulator of energy metabolic homeostasis at the cellular and whole body
levels [1]. AMPK is a serine/threonine kinase that consists of a heterotrimeric complex includ-
ing a catalytic α subunit and regulatory β and γ units [1–3]. There are two isoforms of α (α1
and α2) and β (β1and β2) and three γ subunits (γ1–3), which are differently expressed in mam-
malian tissues [1–3]. AMPK is activated via allosteric regulation of increased AMP concentra-
tion and by the phosphorylation of α subunit (Thr172) via several upstream kinases [1–3]. The
AMPK signaling plays a key role in cellular and organismal survival during stress by its ability
to maintain metabolic homeostasis. Interestingly, there is emerging evidence that activation of
AMPK can suppress activation of nuclear factor-κB (NF-κB), a key regulator of innate immu-
nity and inflammation [3].
The transcription factor NF-κB has been well recognized as a pivotal regulator of inflamma-
tion in rheumatoid arthritis (RA) [4, 5]. RA is a disabling chronic inflammatory autoimmune dis-
ease affecting synovial joints [6]. Experimental evidence suggests that NF-κB activation plays a
pivotal role both at the stage of initiation and the stage of perpetuation of chronic inflammation
in RA, including development of T helper 1 responses, activation, abnormal apoptosis and prolif-
eration of RA fibroblast-like synovial cells, and differentiation and activation of bone resorbing
activity of osteoclasts. In agreement with this, studies in animal models of RA have demonstrated
the high therapeutic efficacy of specific inhibitors of NF-κB signaling pathway [7].
Activation of AMPK can be achieved by pharmacological activators such as AICAR and A-
769662. AICAR activates AMPK by increasing cellular ZMP (a homologue of AMP):ATP
ratio. It has been extensively used in multiple cell lines and some autoimmune diseases [8–10].
However, it suffers from unfavorable pharmacokinetic properties (high effective concentration,
poor bioavailability and short half life), severe metabolic complications (e.g., lactic acidosis and
massive uric acid production) and lack of a strict specificity for AMPK as it interacts with other
enzymes, such as S-adenosylhomocysteine hydrolase and glycogen phosphorylase. In compari-
son, A-769662 is a specific and direct AMPK activator by binding directly to AMPK β1 subunit
at a site distinct from the nucleotides, causing a direct allosteric activation and inhibition of
dephosphorylation [11].
In this study, we tested the effect of A-769662 in inflammatory arthritis in mice. We found
that AMPK activation by A-769662 reduced inflammatory infiltration and joint damage in two
different animal models of inflammatory arthritis. In addition, IL-6 expression in serum and
arthritic joints was significantly decreased in A-769662 treated mice. Moreover, AMPK activa-
tion in BMDMs by A-769662 reduced IL-6 expression and secretion, phosphorylation of p65
NF-κB (ser536) and phosphorylation of ERK and p38 MAPKs in response to TLR4 agonist
LPS. Our data suggest that direct activation of AMPK could be potentially used as a therapeutic
option in inflammatory arthritis.
Material and Methods
Mice
KRN T cell receptor (TCR) transgenic mice on the C57BL/6 background were a gift from Drs.
D. Mathis and C. Benoist (Harvard Medical School, Boston, MA) and Institut de Génétique et
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de Biologie Moléculaire et Cellulaire (Strasbourg, France). AMPKα1 KO mice were generated
by Dr. Benoit Viollet’s group. Ampkα1+/+ and Ampkα1−/−mice in C57BL/6×129/Sv mixed
background were used. Serum transfer and antigen induced arthritis models were induced in
C57BL/6 background mice. Mice used in these experiments were 8–12 weeks old. All animal
protocols received prior approval by the University of California at San Diego Institutional
Animal Care and Use Committee (IACUC) and follow the NIH Guide for the Care and Use of
Laboratory Animals.
Preparation of BMDMs
To generate BMDMs, bone marrow cells from C57BL/6 background mice, were cultured in
DMEM (Invitrogen) with 10% FBS and 20% L929 supernatant containing macrophage-stimu-
lating factor for 6 days and were replated for the assays as indicated. Ampkα1+/+ and Ampkα1−/
− BMDMs were generated from a C57BL/6×129/Sv mixed background.
Reagents
A-769662 was purchased from LC Labs (Woburn, MA) Lipopolysaccharide (LPS; Escherichia
coli 0111:B4) and Pam3C were purchased from Sigma (St. Louis, MO).
Real-time quantitative PCR (qPCR)
BMDMs and joints were collected. Joints were dissected to remove extra-articular tissue, and
snap frozen in liquid nitrogen. The specimens were then pulverized. Total RNA was extracted
with Trizol (Invitrogen) and reverse-transcribed with random hexamers and Superscript II Kit
(Invitrogen). qPCR was performed with SYBR Green PCR Master Mix Kit (Applied Biosys-
tems, Foster City, CA). The relative amounts of transcripts were compared to those of HRPT
and normalized to untreated samples by the ΔΔCt method. Primer sequences are available upon
request.
Western blot analysis
BMDMs and mouse joint tissues were disrupted in lysis buffer (PhosphoSafe™, Novagen,
Gibbstown, NJ) containing a protease inhibitor cocktail. Proteins were separated by
SDS-PAGE and transferred to a nitrocellulose membrane. Blots were probed with antibodies
against phospho-AMPKα (Thr172), total AMPKα, phospho-p65 (Ser536), total p65, phospho-
p38 (Thr180/Tyr182), total p38, phospho-ERK (Thr202/Tyr204), total ERK, phospho-ACC
(Ser79) and total ACC (Cell Signaling Technology, Denvers, MA). Horseradish peroxidase-
conjugated anti-IgG (Cell Signaling Technology, Danvers, MA) was used as secondary anti-
body. Membranes were developed using a chemiluminescence system (ECL detection reagent:
Amersham Life Science, Aylesbury, UK). Densitometry analysis was done using Quantity One
1-D analysis software (Bio-Rad).
Cytokine and nitric oxide (NO) quantification
The conditioned media was used to measure release of IL-1β and IL-6, and NO by DuoSet
enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN) and Griess
method (Cayman Chemicals, Ann Arbor, MI), respectively, following manufacturers’ protocol.
Serum transfer and arthritis scoring
Sera from arthritic adult K/BxN mice were pooled and recipient mice were injected intraperito-
neally (i.p.) with 150 μl of K/BxN serum on day 0. A-769662 (30 and 60mg/kg/bid) was
AMPK Activation in Inflammatory Arthritis
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injected daily i.p. beginning on day 0. Control group was injected with the same amount of
DMSO as needed to dissolve the mentioned drugs. Clinical arthritis scores were evaluated as
described [12].
Antigen-induced arthritis (AIA) induction
Experimental AIA was induced by injection of 100 μg of methylated bovine serum albumin
(mBSA) emulsified in 100 μl of complete Freund’s adjuvant (CFA) subcutaneously (s.c.) in the
flank and then another injection one week later of 100 μg of mBSA/CFA intradermally (i.d.) in
the tail base. Two weeks after these injections, arthritis was induced by intraarticular injection
of 60 μg of mBSA in 10 μl of saline into the right knee joint. The left knee was injected with
saline or PBS to serve as a control. A-769662 (60mg/kg/bid) was injected daily intraperitoneally
(i.p.) beginning on day 0 or day 5 after intraarticular injection. Disease was assessed 10 days
post-intraarticular injection by histological analysis as described below.
Histology analysis
Joints were fixed in 10% formalin, decalcified in formic acid for 3 days, and paraffin embedded.
Sections were prepared from the tissue blocks and stained with hematoxylin and eosin (H&E)
and safranin O. A blinded semiquantitative scoring system was used to assess synovial inflam-
mation, bone erosion and cartilage damage (0–4 scale), as previously described [12].
Determination of serum antibodies
Methylated BSA-specific IgG1 and IgG2b antibodies were measured in sera of individuals by
ELISA. Antigen was coated on microtiter plates at a concentration of 10 μg/ml. Antibody titers
were assessed by 2-fold serial dilutions of sera, followed by detection of bound mouse Ig with a
1:500 dilution of peroxidase-conjugated rabbit anti-mouse Ig. O-phenylenediamine was used
as substrate for the peroxidase reactions.
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). Mann Whitney U test was
used for pair-wise comparisons and ANOVA for multiple group comparisons. All statistical
analyses were performed using PRISM version 4.0b (GraphPad Software, San Diego, Califor-
nia). Results were considered significant for p<0.05.
Results
Effect of AMPK activation by A-769662 on BMDM function
As macrophages are considered the principal innate immune effector cells of rheumatoid
arthritis, we determined the effect in vitro of the specific AMPK pharmacological activator A-
769662 on BMDMs. We first evaluated activation of AMPKα in cultured primary BMDMs
stimulated with A-769662. As shown in Fig 1A, phosphorylation of AMPKα Thr172 was
enhanced by A-769662 at all doses tested. A-769662 (100 μM) was able to inhibit LPS-induced
phosphorylation p65 NF-κB, phosphorylation of Erk1/2 MAPK, and phosphorylation of p38
MAPK (Fig 1B and S1 Fig) in BMDM stimulated with LPS. It also inhibited IL-6 secretion of
BMDMs stimulated with Pam3Cys4 and LPS (Fig 2A), NO release (Fig 2B) and iNOS and IL-6
mRNA expression (Fig 2C and 2D) after LPS stimulation. However other cytokines such as
TNF and chemokines such as CXCL1 were not affected by A-769662 treatment (Fig 2E and
2F). These data suggest that activation of AMPK attenuated inflammatory responses to TLR2
or TLR4 agonists in macrophages in vitro.
AMPK Activation in Inflammatory Arthritis
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A-769662 treatment abrogated joint damage in two murine models of
inflammatory arthritis
Next, we tested the effect of A-769662 on inflammatory arthritis in mice in vivo. We first used
the K/BxN passive serum transfer model, which is dependent on innate but not adaptive
immunity [13]. We observed that phosphorylation of AMPKα and acetyl-CoA carboxylase
(ACC), an AMPK downstream target, in arthritic joint tissues decreased during the peak of
inflammation at day 5 (Fig 3A and S2 Fig), but was increased in mice treated with A-769662
(Fig 3A). We used two different doses (30mg/kg/bid and 60mg/kg/bid) of A-769662. As shown
in Fig 3B and 3C, higher dose of A-769662 significantly lowered clinical score at day 7, and
Fig 1. A-769662 activated AMPKα and regulated NF-κB and MAPK signaling in BMDMs. BMDMs were cultured in the presence of different
concentrations of A-769662 for 2 hours (A), or BMDMs were pre-treated with A-769662 for 2 hours before stimulated with LPS (1 μg/ml) (B). Lysates of
BMDMs were prepared and analyzed for the expression of the indicated proteins byWestern blot (WB). Semi-quantitative densitometry analysis of Western
blots (arbitrary densitometry units) for phosphorylation of indicated proteins normalized to total protein is shown. Results are representative of three
independent experiments.
doi:10.1371/journal.pone.0140452.g001
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ankle swelling from day 3. Histopathological analysis at day 7 showed reduced inflammatory
cell infiltration, joint destruction and cartilage damage in A-769662-treated mice compared
with vehicle-treated controls (Fig 4A and 4B). To evaluate the influence of A-769662 on syno-
vial inflammatory mediators, we determined IL-6 and IL-1β production from these mice on
day 5. Clinical score at day 5 was 12 ± 0.4 and 5.5 ± 1.3 for DMSO and A-769662-treated mice
(0 = 0.002), respectively. Interestingly, amounts of IL-6, but not IL-1β, were significantly lower
in A-769662-treated mice (Fig 4C), suggesting an important role of activation of AMPK in sup-
pression of IL-6 expression.
We also studied the effect of the A-769662 in another model of inflammatory arthritis, the
antigen induced arthritis (AIA) model, which was shown to be macrophage dependent as well
in its effective phase [14]. Clinical and histologic analysis showed a reduction in knee thickness,
inflammatory cell infiltration, and significantly decreased joint destruction and cartilage dam-
age in A-769662-treated mice (Fig 5A and 5B). Humoral immunity, tested by the relative levels
of mBSA-specific antibodies in sera, was also comparable in all mice treated (data not shown).
Fig 2. AMPK inhibited IL-6 and NO production in BMDMs stimulated with TLR2 and TLR4 agonists. (A,B) BMDMs were pre-treated with A-769662
(100, 250 or 500 μM) for 2 hours before stimulated with LPS (1 μg/ml) and Pam3Cys4 (1 μg/ml) for 18 hours. The conditioned media was subjected to ELISA
and Griess reaction for the indicated cytokine and NO release, respectively. (C,D) BMDMs were pre-treated with A-769662 (100 μM) for 2 hours before
stimulated with LPS for two hours. RNA was isolated and analyzed for the expression of the indicated genes. (E,F) BMDMs were pre-treated with A-769662
(100 μM) for 2 hours before stimulated with LPS (1 μg/ml) and Pam3Cys4 (1 μg/ml) for 18 hours. The conditioned media was subjected to ELISA for the
indicated cytokines. Results are expressed as means ± SEM.* p< 0.05 vs DMSO; ** p<0.01; *** p<0.001 and are representative of four independent
experiments.
doi:10.1371/journal.pone.0140452.g002
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Importantly, A-769662 treatment not only prevented the onset of arthritis but also successfully
suppressed joint damage in mice if treatment was initiated in established disease (Fig 5A and
5B). IL-6 amounts in both joints and serum were also significantly lower in A-769662-treated
mice in this model of inflammatory arthritis. (Fig 5C and 5D), confirming the role of AMPK
activation in inhibition of IL-6 secretion in inflammation.
Fig 3. A-769662 treatment activated AMPK in joints and diminished clinical arthritis in passive K/BxN arthritis.WTmice were injected with 150μl
serum from adult K/BxNmice on day 0 to induce arthritis. A-769662 was administrated twice a day from day 0. (A) Proteins of joint tissues from naive and
arthritic mice injected with control vehicle (DMSO) and A-769662 (60mg/kg) were extracted and analyzed for phospho-AMPKα, phosphor-ACC, total AMPKα
and total ACC byWB. D as DMSO and A as A-796662. Semi-quantitative densitometry analysis of Western blots (arbitrary densitometry units) for
phosphorylation of AMPKα and ACC normalized to total AMPKα and ACC respectively is shown. (B) Clinical score at day 7 in mice treated with vehicle, A-
769662 at high (60mg/kg) and low dose (30mg/kg) (n = 5 mice per group). (C) Ankle thickness in DMSO-treated animals (black circles, n = 9) and high dose
A-769662-treated animals (black squares, n = 5) injected with 150 μl of K/BxN serum on day 0. Values are means ± SEM. * = p<0.05; ** = p<0.01.
doi:10.1371/journal.pone.0140452.g003
AMPK Activation in Inflammatory Arthritis
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AMPKα1 deficiency mildly enhanced inflammatory arthritis
We finally induced arthritis in AMPKα1 deficient mice. AMPKα1 is the predominant isoform
in macrophages. Although clinical scores (score at day 6 was 3.4 ± 0.6 and 5.6 ± 0.48, and ankle
thickness was 0.43 ± 0.26 and 0.76 ± 0.21 for WT and AMPKα1 deficient mice respectively, Fig
6A) and amounts of IL-6 in the joints at day 6 (Fig 6B), were increased in the AMPKα1 defi-
cient mice, clinical scores at later time points (Fig 6C) and histologically score at day 8 (data
not shown) were not significantly different between WT and AMPKα1 deficient mice, suggest-
ing that inhibition of both AMPKα isoforms may be needed to sufficiently enhance inflamma-
tory arthritis as other cell types, and not only macrophages, may also play an important role in
this murine model.
Discussion
It has long been established that the development of chronic auto-inflammatory conditions,
including RA and several cardiovascular diseases, is associated with elevated levels of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF [15–17]. Since AMPK activation was
demonstrated to inhibit several pro-inflammatory cytokines in several cell types such as mac-
rophage [18–20], adipocytes [21] and endothelial cells [22], activation of AMPK has been sug-
gested as a target for inflammatory diseases. Furthermore, the AMPK activator AICAR has
been demonstrated to attenuate disease progression in several in vivomodels of inflammation
including a rat model of autoimmune encephalomyelitis, a mouse lung injury model and a
murine model of colitis [8–10]. Interestingly, metformin, a drug used in the clinic for type 2
diabetes that activates AMPK indirectly, was shown to modestly attenuate inflammation in a
murine model of inflammatory arthritis [23]. Given the fact that AMPK activity (indicated by
Fig 4. A-769662 treatment abrogated joint damage and IL-6 expression in passive K/BxN arthritis. (A) Representative H&E and Safranin O stained
sections of ankle joints on day 7 of arthritis induction in DMSO and A-769662-treated mice. Magnification 200x original. Black arrows in H&E stained sections
show joint inflammation and white arrows in Safranin O stained sections show cartilage damage that was reduced in A-769662-treated ankles. (B)
Histological scores for joint inflammation, erosion and cartilage damage in vehicle and high dose A-769662-treated mice on day 7 after serum transfer. (C)
Proteins of joint tissues from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of DMSO and A-769662-treated mice were extracted and
analyzed by ELISA for the presence of the indicated cytokines.
doi:10.1371/journal.pone.0140452.g004
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phosphorylation of AMPKα) decreased in macrophages upon pro-inflammatory stimulus
(LPS) in vitro, and in joints during the peak of inflammatory arthritis in vivo, and the ability of
A-769662 to prevent inhibition of inflammatory responses, AMPK could be a promising phar-
macologic target in arthritis [24].
Most of the agents described as AMPK activators activate AMPK indirectly by inhibiting
mitochondrial function (e.g. metformin, berberine), altering cellular AMP levels (e.g. metho-
trexate), and increasing cellular ZMP, an AMP mimetic nucleotide (e.g. AICAR). AICAR has
been found to have AMPK independent effects due to interaction of ZMP with other AMP reg-
ulated enzymes and increase of the level of cAMP [25]. Metformin, on the other hand, affects
primarily the liver, probably because hepatocytes express the organic cation transporter OCT1,
which is needed for metformin transport into cells. Interestingly, immune cells do not express
OCT1 transporter [26]. Therefore, there has been a major effort to develop more specific and
Fig 5. A-769662 treatment also abrogated joint damage and IL-6 expression in AIA. (A) Representative H&E and Safranin O stained sections of knee
joints on day 10 of AIA induction in vehicle and A-769662-treated mice, which were treated either at day 0 or day 4 after intraarticular injection of mBSA (n = 5
mice per group). Original magnification 200x. (B) Knee thickness in A-769662-treated mice on day 10 of AIA induction. (C) Sections of knee joints were
scored for inflammatory infiltration, bone erosion and cartilage damage. A-769662-treated mice had significantly lower scores thanWT. (D) Proteins of joint
tissues from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of vehicle and A-769662-treated mice were extracted and analyzed by
ELISA for the presence of IL-6. (E) Serum from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of vehicle and A-769662-treated mice
was analyzed by ELISA for IL-6. Results are expressed as means ± SEM.* p< 0.05 vs WTmice; ** p<0.01
doi:10.1371/journal.pone.0140452.g005
AMPK Activation in Inflammatory Arthritis
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direct activators, while avoiding some of their side effects, which may be related to inhibition of
the respiratory chain rather than to activation of AMPK per se. The thienopyridone A-769662
[11] is the first described and certainly the most potent and specific pharmacological activator
of AMPK available at present [27]. Although it was shown that AMPKα1 is the dominant
AMPKα isoform expressed in macrophages, AMPKα2 has a more prominent role in other cell
types that can also been involved in inflammatory arthritis, so activation of both isoforms are
preferable. Further research is needed to identify in which type of infiltrating cells in arthritic
joints AMPK is activated by A-769662. More important, because of its specificity, A-769662
lacks the off-target effects of AICAR and metformin. In fact, a recent work showed that the
majority of these agonists display AMPK-independent effects on several functions with only
the synthetic activator A-769662 exerting AMPK-dependent effects on cell proliferation and
metabolism [28]. However, we cannot rule out that this drug may also have other activities
toward different enzymes in the dosage used in both in vitro and in vivo experiments as
described [29, 30].
A plethora of studies have demonstrated that activation of AMPK suppresses NF-κB signal-
ing, via its downstream mediators including SIRT1, Forkhead box O (FoxO) family, and perox-
isome proliferator-activated receptor γ co-activator 1α (PGC-1α) [31], which can subsequently
repress the expression of NF-κB-dependent inflammatory factors such as cytokine IL-6. In
macrophage cell lines, constitutively active AMPK reduces LPS-stimulated IκBα degradation
and subsequent p65 binding to the IL-6 promoter [32]. As murine models of inflammatory
arthritis are only partially IL-6 dependent, this could explain why targeting this pathway in
murine models with other indirect AMPK agonists in earlier studies had shown only a mild
effect. Targeting this pathway in RA seems though an attractive option, as IL-6 is important for
both joint destruction and systemic manifestations [33]. Currently, tocilizumab, which binds
the IL-6 receptor, is licensed for treatment in active, moderate to severe disease in RA. Elevated
lipid profiles with the use of this drug are frequent although more evidence is needed on the
long-term cardiovascular safety. Yet, A-769662 was also shown to have beneficial effects on
both hepatic steatosis and insulin resistance, thus emphasizing the potential therapeutic impli-
cations for AMPK activation in anti-IL-6 responsive RA patients and associated metabolic syn-
drome [34].
The JNK, p38 and ERK1/2 mitogen-activate protein kinases (MAPKs) pathways also play
key roles in inflammatory signaling [35], particularly in rheumatoid arthritis. MAPKs have
Fig 6. AMPKα1 deficiency mildly increased clinical arthritis in K/BxN arthritis.WTmice and AMPKα1 KO were injected with 100μl serum from adult K/
BxNmice on day 0 to induce arthritis. (A) Clinical score and ankle thickness in WT and AMPKα1 deficient animals (n = 5 mice per group) at day 6 after
arthritis induction. (B) Proteins of joint tissues from naive (n = 4 mice per group) and arthritic mice (n = 4 mice per group) of WT and AMPKα1 deficient mice
were extracted at day 6 after arthritis induction and analyzed by ELISA for the presence of IL-6. (C) Clinical score in WT animals (black circles, n = 6) and
AMPKα1 animals (black squares, n = 6). Values are means ± SEM. * = p<0.05; ** = p<0.01.
doi:10.1371/journal.pone.0140452.g006
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been implicated as playing important regulatory roles in the production of pro-inflammatory
cytokines and downstream signaling events leading to joint inflammation and destruction. A
few studies have identified AMPK-dependent suppression of cytokine-stimulated MAPK phos-
phorylation/activation [3]. For instance, berberine has been demonstrated to inhibit LPS-stim-
ulated JNK, ERK1/2 and p38 MAPK phosphorylation in an AMPK-dependent manner in
macrophages [19]. Similarly, A769662 inhibited palmitate-stimulated ERK1/2 phosphorylation
in an AMPK-dependent manner in L6 myotubes [36]. Although AICAR has been reported to
be associated with enhanced TNF-stimulated JNK and p38 phosphorylation in human colon
adenocarcinoma cells [37], in BMDMs both A-769662 and AICAR decrease p38 and ERK--
MAPK phosphorylation after TNF induction.
Taken together, our in vitro and in vivo studies suggest that AMPK activation might be ben-
eficial in inflammatory arthritis by suppressing macrophage inflammatory responses, including
IL-6 secretion and activation of NK-κB and MAPK. Therefore, the data provide a rationale for
a novel strategy of targeted activation of AMPK as a therapeutic approach in RA.
Key Messages
• AMPK activation exert significant anti-inflammatory and immunosuppressive effects
• AMPK activation suppressed inflammatory arthritis as well as IL-6 expression in serum and
arthritic joints.
• Targeted activation of AMPK might be an effective therapeutic strategy for IL-6 dependent
inflammatory arthritis.
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S1 Fig. Semi-quantitative densitometry analysis of Western blots (arbitrary densitometry
units) for phosphorylation of indicated proteins normalized to total protein is shown.
Results are average of three independent experiments.  p<0.01 vehicle vs A-769662 treated
cells.
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S2 Fig. Semi-quantitative densitometry analysis of Western blots (arbitrary densitometry
units) for phosphorylation of AMPKα and ACC normalized to total AMPKα and ACC
respectively is shown.NS: not significant;  p<0.05,  p<0.01,  p<0.001.
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